New hope for tough breast cancer: SKB264 trial targets Chemo-Resistant tumors
NCT ID NCT06081959
First seen Jan 03, 2026 · Last updated Apr 24, 2026 · Updated 16 times
Summary
This study tests a new drug called SKB264 against standard chemotherapy in people with advanced HR+/HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if SKB264 can slow cancer growth or improve survival. About 376 adults aged 18-75 with measurable tumors will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Science
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
Conditions
Explore the condition pages connected to this study.